TY - THES A1 - Gründel, Sindy T1 - Akuteffekte des polyphenolreichen unlöslichen Carobballaststoffes auf Parameter des Metabolischen Syndroms bei gesunden Erwachsenen T1 - Acute effects of carob fibre preparation rich in polyphenols on parameters of the metabolic syndrome in healthy adults N2 - Das Metabolische Syndrom stellt eine Kombination verschiedener metabolischer Anomalien in einem Individuum dar. Starkes Übergewicht gilt als maßgebende Größe in der Genese des Syndroms, welches mit einem enormen Risiko für kardiovaskuläre Erkrankungen einhergeht. Um die stark steigende Prävalenz des Metabolischen Syndroms einzudämmen, sind dringend Konzepte für die Behandlung, vor allem jedoch für die Prävention von Übergewicht erforderlich. Einen wichtigen Beitrag leisten diesbezüglich Ballaststoffe in der Ernährung. Sie tragen auf unterschiedlichen Wegen zur Gewichtskontrolle bei und beeinflussen zudem verschiedene mit dem Metabolischen Syndrom assoziierte Blutparameter. Ebenso werden protektive Effekte von Polyphenolen, welche zur Gruppe der sekundären Pflanzenstoffe zählen, beschrieben. Diese wirken u. a. auf den Glukose- sowie den Insulinhaushalt und greifen darüber hinaus in die Regulation der Fettverbrennung sowie des Energieverbrauches ein. Die Kombination beider Substanzgruppen verspricht bedeutendes gesundheitsförderndes Potential; dieses wurde gegenwärtig jedoch kaum untersucht. Carobballaststoff ist ein polyphenolreicher und vorwiegend unlöslicher Extrakt der Frucht des Johannisbrotbaumes (Ceratonia siliqua L). Bislang publizierte Studien zur physiologischen Wirksamkeit dieses Ballaststoffpräparates weisen sowohl beim Tier als auch beim Menschen bemerkenswerte hypocholesterinämische Eigenschaften nach. Inwiefern sich der Verzehr des Carobballaststoffes ebenso auf die Entwicklung von Übergewicht sowie anderen Messgrößen des Metabolischen Syndroms auswirkt, ist allerdings nicht bekannt. Die Zielstellung der Promotionsarbeit bestand darin, die postprandialen Wirkungen des Carobballaststoffverzehrs mit Hilfe einer Humanstudie aufzuzeigen. In die randomisierten, einfach verblindeten Untersuchungen im cross-over-Design wurden 20 gesunde Erwachsene im Alter zwischen 22 und 62 Jahren eingeschlossen. Unter Verwendung variierender Begleitmahlzeiten wurden die postprandialen Effekte verschiedener Mengen des Carobballaststoffes untersucht. Hierbei standen die Veränderungen der Plasmakonzentrationen von Glukose, Triglyceriden (TG), totalem und acyliertem Ghrelin sowie der Serumkonzentrationen von Insulin und nicht-veresterten Fettsäuren (NEFA) im Mittelpunkt der Betrachtungen. Der Verzehr des Carobballaststoffes in Kombination mit 200 ml Wasser und 50 g Glukose erhöhte die postprandialen Glukose- und Insulinkonzentrationen gegenüber der Glukoselösung ohne Ballaststoffzusatz. In Kombination mit 400 ml einer Flüssigmahlzeit verzehrt, senkte Carobballaststoff die postprandialen TG-, NEFA- und Ghrelin- (acyliert) Antworten. Die Untersuchung des respiratorischen Quotienten nach Zusatz von Carobballaststoff zur Flüssigmahlzeit mittels indirekter Respirationskalorimetrie bekräftigte die bereits bekannten Effekte auf den Lipidmetabolismus und wies zudem eine Steigerung der Fettverwertung unter Verminderung der Glukoseoxidation nach. Wurde Carobballaststoff schließlich in Lebensmittel eingebracht, sanken nach dem Verzehr dieser Lebensmittel erneut die postprandialen Konzentrationen an TG und NEFA. Gleichzeitig erhöhten sich die Glukose-, Insulin- sowie Ghrelin- (acyliert) Antworten. Carobballaststoff löst in Abhängigkeit von der jeweils verzehrten Begleitmatrix unterschiedliche Effekte aus. Das Präparat weist beachtliche Wirkungen auf die Blutlipide sowie den Energieverbrauch auf, hat indes ungünstige Wirkungen auf die Blutglukose, sofern er in Kombination mit einer veränderten Nährstoffmatrix aufgenommen wird. Carobballaststoff besitzt starkes gesundheitsförderndes Potential; jedoch sind weitere Studien notwendig, um seine Wirkungen sowie deren Voraussetzungen besser zu verstehen. Ferner sollten Untersuchungen über einen längeren Zeitraum vorgenommen werden, um die langfristige Relevanz der gewonnenen Ergebnisse darzulegen. Danach stellt die Anreicherung spezieller Lebensmittel mit Carobballaststoff einen geeigneten Weg dar, um von den viel versprechenden protektiven Wirkungen des Präparates zu profitieren. N2 - The metabolic syndrome is a clustering of metabolic abnormalities and cardiovascular risk factors that occur in one individual. Since many individuals suffering of the metabolic syndrome are overweight, dietary treatment should primarily focus on weight reduction and control to handle and, much more importantly, to prevent the genesis of the syndrome. Dietary fiber could play a role in the management of the metabolic syndrome through its ability to control body weight as well as several parameters associated to the syndrome. Beside this, dietary polyphenols have been shown to influence glucose and insulin metabolism. Furthermore, studies in mice and men showed that polyphenols might increase fat oxidation and energy expenditure. The combination of both, dietary fiber and polyphenols, may exert beneficial health effects, which are not known up to now. A polyphenol-rich insoluble dietary fiber preparation from carob pulp (Ceratonia siliqua L; carob fiber) showed significant hypocholesterolemic activity in different animal trails and two human studies indicating that carob fiber may have potent health effects. However, short term effects on parameters associated with the control of the metabolic syndrome are not known. Therefore, a study was conducted to investigate the postprandial effects of carob fiber in healthy humans using different background food matrices. The study was designed as a randomized single-blind cross-over study in 20 subjects, aged 22 to 62 years. During several examinations plasma glucose, triglycerides (TG), total and acylated ghrelin, cholecystokinin (CCK) and peptide YY (PYY) as well as serum insulin and non-esterified fatty acids (NEFA) were repeatedly assessed before and after ingestion of carob fiber in combination with different test meals. The study results showed that carob fiber, consumed within a glucose load, increased plasma glucose and serum insulin compared to control. Plasma PYY increased after consumption of carob-enriched glucose solution. In a second part of the study, postprandial changes were assessed before and after ingestion of an isocaloric standardized liquid meal with or without carob fiber. Carob fiber intake lowered acylated ghrelin, triglycerides, and NEFA compared to control meal. Postprandial energy expenditure was increased and RQ was reduced after liquid meal with carob fiber compared to control meal. Finally, effects of the consumption of carob fiber-enriched foods were investigated at the subsequent day. Enrichment of foods increased plasma glucose and acylated ghrelin responses. Plasma triglycerides and serum NEFA responses were lower after bread ingestion compared to control. These results indicate that the effects of polyphenol-rich carob fiber on different blood parameters depend on the meal composition. Carob fiber showed beneficial effects on blood lipids as well as energy homeostasis, but also a deteriorated glycemic control when administered within a different food matrix. Further studies are needed to clarify observed effects and the mechanisms behind. Additionally, present study shows only short-term effects of carob fiber consumption, which might be less pronounced after long-term consumption due to adaptation mechanisms. Thus, future studies should elucidate the relevance of observed effects in long-term. KW - Carobballaststoff KW - Polyphenole KW - Metabolisches Syndrom KW - Substratverwertung KW - carob fibre KW - polyphenols KW - metabolic syndrome KW - substrate utilisation Y1 - 2007 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:kobv:517-opus-14899 ER - TY - THES A1 - Wegewitz, Uta Elke T1 - Genetische und metabolische Regulation von Adiponectin : Resultate von in vitro und humanen in vivo Studien T1 - Genetic and metabolic regulation of adiponectin : results of in vitro and human in vivo studies N2 - Übergewicht, Diabetes oder Fettstoffwechselstörungen sind mit erniedrigten Adiponectinspiegeln assoziiert. Eine Modulation des Adiponectins kann durch genetische und metabolische Gegebenheiten erfolgen. Das Ziel dieser Arbeit war die Analyse von Faktoren, welche die Adiponectinspiegel beeinflussen können, sowie eine Charakterisierung der Oligomerverteilung unter verschiedenen metabolischen Bedingungen. In der MeSyBePo-Kohorte waren die zirkulierenden Adiponectinspiegel mit den Promotorpolymorphismen ADIPOQ -11377 C/G und ADIPOQ -11391 G/A im Adiponectingen assoziiert. Im Hinblick auf die metabolischen Faktoren korrelierte Adiponectin eng mit Parametern des Glukose- und Fettstoffwechsels sowie dem Übergewicht. Innerhalb von hyperinsulinämischen euglykämischen Clamps führte eine akute Hyperinsulinämie zu einer Abnahme der Adiponectinspiegel. Adiponectin zirkuliert im Serum als hochmolekulare (HMW), mittelmolekulare (MMW) und niedrigmolekulare (LMW) Spezies. Mit zunehmendem Körpergewicht konnte eine Verlagerung von HMW-Spezies hin zu den LMW-Spezies beobachtet werden. Durch eine moderate Gewichtsabnahme erhöhten sich die Anteile an HMW- und MMW-Adiponectin wieder. Während sich in Abhängigkeit vom Glukosemetabolismus keine Unterschiede in den Gesamtspiegeln ergaben, wurden bei Personen mit normaler Glukosetoleranz signifikant höhere Anteile an MMW-Adiponectin detektiert als bei Personen mit einem gestörten Glukosestoffwechsel. Insgesamt scheinen die HMW- und MMW-Spezies gegensätzlich zur LMW-Spezies reguliert zu werden. Die Arbeit unterstreicht die wichtige Rolle des Adiponectins im Glukose- und Fettstoffwechsel sowie bei einer Adipositas in vivo. Dabei waren Änderungen der Adiponectinspiegel bei Vorliegen von Insulinresistenz und Adipositas stets mit einer Umverteilung der Oligomerfraktionen verbunden. Vor allem die HMW- und MMW-Spezies des Adiponectins scheinen von entscheidender Bedeutung zu sein. N2 - Experimental data suggest that a dysregulation of adiponectin might be involved in the development of the metabolic syndrome. Adiponectin circulates as a variety of multimeric forms and its concentration was found to be decreased in obesity, type 2 diabetes mellitus, and dyslipidemia. Polymorphisms within the adiponectin gene, as well as the metabolic status, may modulate the adiponectin level. The aim of this work was to evaluate factors that may modulate total adiponectin levels as well as the distribution of its multimeric complexes under specific metabolic conditions. In the caucasian MeSyBePo population, serum adiponectin concentrations were associated with two promoter polymorphisms, ADIPOQ -11377 C/G and ADIPOQ -11391 G/A, respectively. Mean serum adiponectin levels were related to obesity, glucose metabolism, and lipid metabolism. Additionally, hyperinsulinemic euglycemic clamps acutely lowered serum adiponectin concentration. Adiponectin circulates in serum as low-, medium-, and high-molecular-weight complexes (LMW, MMW, and HMW, respectively). Adiponectin oligomer composition was related to BMI, with decreased HMW and MMW fractions in case of high BMI levels. According to this, HMW and MMW adiponectin increased after moderate weight reduction. While total adiponectin levels were comparable between patients with type 2 diabetes and control subjects, a reduction of MMW oligomers was observed in patients with impaired glucose metabolism. Finally, these studies all suggested a differential regulation of HMW and MMW species compared to the LMW fraction. The data presented underline the important role of adiponectin within the glucose- and lipid metabolism as well as in obesity. We showed that modulation of total adiponectin levels in case of insulin resistance or obesity are always accompanied with changes of adiponectin oligomer composition. Thereby the HMW and MMW species seem to play a crucial role in affecting metabolic changes. KW - Adioponectin KW - Adipositas KW - Typ-2-Diabetes mellitus KW - Metabolisches Syndrom KW - Oligomere KW - adiponectin KW - obesity KW - type 2 diabetes mellitus KW - metabolic syndrome KW - oligomers Y1 - 2007 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:kobv:517-opus-16062 ER - TY - JOUR A1 - Manowsky, Julia A1 - Camargo, Rodolfo Gonzalez A1 - Kipp, Anna Patricia A1 - Henkel, Janin A1 - Püschel, Gerhard Paul T1 - Insulin-induced cytokine production in macrophages causes insulin resistance in hepatocytes JF - American journal of physiology : Endocrinology and metabolism N2 - Overweight and obesity are associated with hyperinsulinemia, insulin resistance, and a low-grade inflammation. Although hyperinsulinemia is generally thought to result from an attempt of the beta-cell to compensate for insulin resistance, there is evidence that hyperinsulinaemia itself may contribute to the development of insulin resistance and possibly the low-grade inflammation. To test this hypothesis, U937 macrophages were exposed to insulin. In these cells, insulin induced expression of the proinflammatory cytokines IL-1 beta, IL-8, CCL2, and OSM. The insulin-elicited induction of IL-1 beta was independent of the presence of endotoxin and most likely mediated by an insulin-dependent activation of NF-kappa B. Supernatants of the insulin-treated U937 macrophages rendered primary cultures of rat hepatocytes insulin resistant; they attenuated the insulin-dependent induction of glucokinase by 50%. The cytokines contained in the supernatants of insulin-treated U937 macrophages activated ERK1/2 and IKK beta, resulting in an inhibitory serine phosphorylation of the insulin receptor substrate. In addition, STAT3 was activated and SOCS3 induced, further contributing to the interruption of the insulin receptor signal chain in hepatocytes. These results indicate that hyperinsulinemia per se might contribute to the low-grade inflammation prevailing in overweight and obese patients and thereby promote the development of insulin resistance particularly in the liver, because the insulin concentration in the portal circulation is much higher than in all other tissues. KW - metabolic syndrome KW - type 2 diabetes KW - inflammation KW - macrophage KW - insulin KW - cytokines Y1 - 2016 U6 - https://doi.org/10.1152/ajpendo.00427.2015 SN - 0193-1849 SN - 1522-1555 VL - 310 SP - E938 EP - E946 PB - American Chemical Society CY - Bethesda ER - TY - THES A1 - Gonzalez Camargo, Rodolfo T1 - Insulin resistance in cancer cachexia and metabolic syndrome BT - role of insulin activated macrophages and miRNA-21-5p N2 - The ever-increasing fat content in Western diet, combined with decreased levels of physical activity, greatly enhance the incidence of metabolic-related diseases. Cancer cachexia (CC) and Metabolic syndrome (MetS) are both multifactorial highly complex metabolism related syndromes, whose etiology is not fully understood, as the mechanisms underlying their development are not completely unveiled. Nevertheless, despite being considered “opposite sides”, MetS and CC share several common issues such as insulin resistance and low-grade inflammation. In these scenarios, tissue macrophages act as key players, due to their capacity to produce and release inflammatory mediators. One of the main features of MetS is hyperinsulinemia, which is generally associated with an attempt of the β-cell to compensate for diminished insulin sensitivity (insulin resistance). There is growing evidence that hyperinsulinemia per se may contribute to the development of insulin resistance, through the establishment of low grade inflammation in insulin responsive tissues, especially in the liver (as insulin is secreted by the pancreas into the portal circulation). The hypothesis of the present study was that insulin may itself provoke an inflammatory response culminating in diminished hepatic insulin sensitivity. To address this premise, firstly, human cell line U937 differentiated macrophages were exposed to insulin, LPS and PGE2. In these cells, insulin significantly augmented the gene expression of the pro-inflammatory mediators IL-1β, IL-8, CCL2, Oncostatin M (OSM) and microsomal prostaglandin E2 synthase (mPGES1), and of the anti-inflammatory mediator IL-10. Moreover, the synergism between insulin and LPS enhanced the induction provoked by LPS in IL-1β, IL-8, IL-6, CCL2 and TNF-α gene. When combined with PGE2, insulin enhanced the induction provoked by PGE2 in IL-1β, mPGES1 and COX2, and attenuated the inhibition induced by PGE2 in CCL2 and TNF-α gene expression contributing to an enhanced inflammatory response by both mechanisms. Supernatants of insulin-treated U937 macrophages reduced the insulin-dependent induction of glucokinase in hepatocytes by 50%. Cytokines contained in the supernatant of insulin-treated U937 macrophages also activated hepatocytes ERK1/2, resulting in inhibitory serine phosphorylation of the insulin receptor substrate. Additionally, the transcription factor STAT3 was activated by phosphorylation resulting in the induction of SOCS3, which is capable of interrupting the insulin receptor signal chain. MicroRNAs, non-coding RNAs linked to protein expression regulation, nowadays recognized as active players in the generation of several inflammatory disorders such as cancer and type II diabetes are also of interest. Considering that in cancer cachexia, patients are highly affected by insulin resistance and inflammation, control, non-cachectic and cachectic cancer patients were selected and the respective circulating levels of pro-inflammatory mediators and microRNA-21-5p, a posttranscriptional regulator of STAT3 expression, assessed and correlated. Cachectic patients circulating cytokines IL-6 and IL-8 levels were significantly higher than those of non-cachectic and controls, and the expression of microRNA-21-5p was significantly lower. Additionally, microRNA-21-5p reduced expression correlated negatively with IL-6 plasma levels. These results indicate that hyperinsulinemia per se might contribute to the low grade inflammation prevailing in MetS patients and thereby promote the development of insulin resistance particularly in the liver. Diminished MicroRNA-21-5p expression may enhance inflammation and STAT3 expression in cachectic patients, contributing to the development of insulin resistance. N2 - O teor de gordura cada vez maior na dieta ocidental, combinada com a diminuição dos níveis de atividade física têm marcadamente aumentado à incidência de doenças relacionas ao metabolismo. A caquexia associada ao câncer (CC) e a síndrome metabólica (SM) são síndromes de etiologia complexa e multifatorial, não totalmente compreendida, e com mecanismos subjacentes ao seu desenvolvimento não completamente revelados. No entanto, apesar de serem consideradas "lados opostos", a CC e a MetS apresentam várias características em comum, tais como resistência à insulina e inflamação de baixo grau, com macrófagos teciduais como importantes coadjuvantes, devido à sua capacidade de produzir e liberar mediadores inflamatórios, e microRNAs, descritos como RNAs não-codificantes ligados à regulação da expressão de proteínas e reconhecidos como participantes ativos na geração de várias doenças inflamatórias, tais como o câncer e diabetes tipo II. Uma das principais características da MetS é a hiperinsulinemia, que está geralmente associada com uma tentativa da célula β do pâncreas de compensar a diminuição da sensibilidade à insulina (resistência à insulina). Um número crescente de evidências sugere que a hiperinsulinemia “por si só”, pode contribuir com o desenvolvimento de resistência à insulina através do estabelecimento de um quadro inflamatório de baixo grau, em tecidos sensíveis a insulina, e em particular no fígado, devido ao fato da insulina ser secretada pelo pâncreas na circulação portal. A hipótese do presente estudo foi que a insulina pode induzir uma resposta inflamatória em macrófagos e culminar em diminuição da sensibilidade hepática à insulina. Para confirmar esta hipótese, primeiramente, macrófagos diferenciados da linhagem de células humanas U937 foram expostos à insulina, LPS e PGE2. Nestas células, a insulina aumentou significativamente a expressão gênica dos mediadores pró-inflamatórios IL-1β, IL- 8, CCL2, oncostatina M (OSM) e prostaglandina E2 sintase microssomal (mPGES1), e do mediador anti-inflamatório IL-10. Além disso, o sinergismo entre insulina e LPS aumentou a indução provocada por LPS nos genes da IL-1β, IL-8, IL-6, CCL2 e TNF-α. Quando combinado com PGE2, a insulina aumentou a indução provocada pela PGE2 nos genes da IL-1β, mPGES1 e COX2, e restaurou a inibição induzida pela PGE2 no gene CCL2 e TNF-α.Subsequentemente, sobrenadantes dos macrófagos U937 tratados com insulina modulou negativamente a sinalização da insulina em culturas primárias de hepatócitos de rato, como observado pela atenuação de 50% da indução dependente de insulina da enzima glicoquinase. Citocinas contidas no sobrenadante de macrófagos U937 tratados com insulina também ativaram em hepatócitos ERK1/2, resultando na fosforilação do resíduo de serina inibitório do substrato do receptor de insulina. Adicionalmente, o fator de transcrição STAT3 foi ativado por um elevado grau de fosforilação e a proteína SOCS3, capaz de interromper a via de sinalização do receptor de insulina, foi induzida. Considerando que na caquexia associada ao câncer, pacientes são altamente afetados pela resistência à insulina e inflamação, pacientes controle, não caquéticos e caquéticos foram seleccionados e os respectivos níveis circulantes de mediadores pró-inflamatórios e microRNA-21-5p, um regulador pós-transcricional da expressão de STAT3, avaliados e correlacionados. Pacientes caquéticos exibiram citocinas circulantes IL-6 e IL-8 significativamente maiores do que pacientes não caquéticos e controles, assim como a expressão de microRNA-21-5p significativamente diminuida. Além disso, a reduzida expressão de microRNA-21-5p correlaciona-se negativamente com níveis de IL-6 no plasma. Estes resultados indicam que a hiperinsulinemia pode, por si só contribuir para o desenvolvimento da inflamação de baixo grau prevalente em pacientes com excesso de peso e obesos e, assim, promover o desenvolvimento de resistência à insulina especialmente no fígado e o nível reduzido de miRNA-21-5p pode modular a inflamação e expressão de STAT3 em pacientes caquéticos, contribuindo para o desenvolvimento da resistência à insulina. N2 - Der stetig steigende Fettgehalt in westlicher Ernährung in Kombination mit reduzierter körperlicher Aktivität hat zu einem dramatischen Anstieg der Inzidenz metabolischer Erkrankungen geführt. Tumorkachexie (Cancer cachexia, CC) und Metabolisches Syndrom (MetS) sind sehr komplexe, multifaktorielle metabolische Erkrankungen, deren Ätiologie nicht vollständig verstanden ist. Die molekularen Ursachen, die zu diesen Symptomkomplexen führen, sind noch unzureichend aufgeklärt. Obwohl ihr äußeres Erscheinungsbild stark gegensätzlich ist, haben MetS und CC etliche Gemeinsamkeiten wie zum Beispiel Insulinresistenz und eine chronische unterschwellige Entzündung. Sowohl bei der Entstehung der Insulinresistenz als auch bei der chronischen Entzündung spielen Makrophagen eine Schlüsselrolle, weil sie in der Lage sind pro-inflammatorische Mediatoren zu produzieren und freizusetzen. Eine der hervorstechendsten Auffälligkeiten des MetS ist die Hyperinsulinämie, die durch den Versuch der β-Zelle, die verminderte Insulinsensitivität (Insulinresistenz) zu kompensieren, zustande kommt. Es gibt zunehmend Hinweise darauf, dass die Hyperinsulinämie selber an der Entzündungsentstehung in Insulin-abhängigen Geweben beteiligt ist und dadurch zur Entwicklung und Verstärkung der Insulinresistenz beitragen kann. Dies trifft besonders auf die Leber zu, weil hier die Insulinspiegel besonders hoch sind, da Insulin vom Pankreas direkt in den Pfortaderkeislauf gelangt. Daher wurde in dieser Arbeit die Hypothese geprüft, ob Insulin selber eine Entzündungsantwort auslösen und dadurch die hepatische Insulinsensitivität senken kann. Zu diesem Zweck wurde die humane Zelllinie U937 durch PMA-Behandlung zu Makrophagen differenziert und diese Makrophagen mit Insulin, LPS und PGE2 inkubiert. In diesen Zellen steigerte Insulin die Expression der pro-inflammatorischen Mediatoren IL-1β, IL-8, CCL2, Oncostatin M (OSM) signifikant und induzierte die mikrosomale PGE-Synthase 1 (mPGES1) ebenso wie das antiinflammatorische Cytokin IL-10. Ferner verstärkte Insulin die LPS-abhängige Induktion des IL-1β-, IL-8-, IL-6-, CCL2- und TNFα-Gens. Ebenso verstärkte Insulin die PGE2-abhängige Induktion von IL-1β, mPGES1 und COX2. Im Gegensatz dazu schwächte es die Hemmende Wirkung von PGE2 auf Expression von TNFα und CCL2 ab und trug so auf beide Weisen zu einer Verstärkung der Entzündungsantwort bei. Überstände von Insulin-behandelten U937 Makrophagen reduzierten die Insulin-abhängige Induktion der Glukokinase in Hepatocyten um 50%. Die Cytokine, die im Überstand Insulin-behandelter Makrophagen enthalten waren, aktivierten in Hepatocyten ERK1/2, was zu einer inhibitorischen Serin-Phosphorylierung der Insulin Rezeptor Substrats (IRS) führte. Zusätzlich führten die Cytokine zu einer Phosphorylierung und Aktivierung von STAT3 und einer dadurch bedingten Induktion von SOCS3, das seinerseits die Insulinrezeptor-Signalkette unterbrechen kann. MicroRNAs, nicht-codierende RNAs, die an der Regulation der Proteinexpression beteiligt sind und deren Beteiligung an der Regulation der Entzündungsantwort bei zahlreichen Erkrankungen, unter anderem Tumorerkrankungen und Typ II Diabetes gezeigt wurde, sind auch von Interesse. Unter dem Blickwinkel, dass Tumor-Kachexie Patienten sich durch eine Insulinresistenz und eine systemische Entzündung auszeichnen, wurden in nichtkachektische und tumorkachektische Patienten Plasmaspiegel von pro-inflammatorischen Mediatoren und der microRNA-21-5p bestimmt, von der bekannt ist, dass sie ein posttranskriptioneller Regulator der STAT3 Expression ist. Die Spiegel der proinflammatorischen Mediatoren und der miRNA-21-5p wurden korreliert. In kachektischen Patienten waren die Spiegel der Cytokine IL-6 und IL-8 signifikant höher, die der miRNA-21- 5p signifikant niedriger als in nicht-kachektischen Patienten. Die Plasma IL-6-Spiegel korrelierten negativ mit den miRNA21-5p Spiegeln. Insgesamt zeigen die Ergebnisse, dass eine Hyperinsulinämie selber zu der Entwicklung einer unterschwellingen Entzündung, wie sie in Patienten mit einem MetS vorherrscht, beitragen, und dadurch besonders in der Leber eine Insulinresistenz auslösen oder verstärken kann. Eine verringerte Expression der MicroRNA-21-5p kann in kachektischen Patienten die Entzündungsantwort, im Speziellen die STAT3 Expression, verstärken und dadurch zur Entwicklung einer Insulinresistenz beitragen KW - cachexia KW - metabolic syndrome KW - inflammation KW - insulin resistance KW - microRNAs KW - insulin KW - liver KW - macrophages KW - caquexia KW - síndrome metabólica KW - inflamação KW - resistência à insulina KW - microRNAs KW - insulina KW - fígado KW - macrófagos KW - Kachexie KW - metabolisches Syndrom KW - Entzündung KW - Insulinresistenz KW - MicroRNAs KW - Insulin KW - Leber KW - Makrophagen Y1 - 2016 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:kobv:517-opus4-100973 ER - TY - GEN A1 - Woting, Anni A1 - Blaut, Michael T1 - The intestinal microbiota in metabolic disease T2 - Nutrients N2 - Gut bacteria exert beneficial and harmful effects in metabolic diseases as deduced from the comparison of germfree and conventional mice and from fecal transplantation studies. Compositional microbial changes in diseased subjects have been linked to adiposity, type 2 diabetes and dyslipidemia. Promotion of an increased expression of intestinal nutrient transporters or a modified lipid and bile acid metabolism by the intestinal microbiota could result in an increased nutrient absorption by the host. The degradation of dietary fiber and the subsequent fermentation of monosaccharides to short-chain fatty acids (SCFA) is one of the most controversially discussed mechanisms of how gut bacteria impact host physiology. Fibers reduce the energy density of the diet, and the resulting SCFA promote intestinal gluconeogenesis, incretin formation and subsequently satiety. However, SCFA also deliver energy to the host and support liponeogenesis. Thus far, there is little knowledge on bacterial species that promote or prevent metabolic disease. Clostridium ramosum and Enterococcus cloacae were demonstrated to promote obesity in gnotobiotic mouse models, whereas bifidobacteria and Akkermansia muciniphila were associated with favorable phenotypes in conventional mice, especially when oligofructose was fed. How diet modulates the gut microbiota towards a beneficial or harmful composition needs further research. Gnotobiotic animals are a valuable tool to elucidate mechanisms underlying diet-host-microbe interactions. T3 - Zweitveröffentlichungen der Universität Potsdam : Mathematisch-Naturwissenschaftliche Reihe - 448 KW - intestinal microbiota KW - obesity KW - diabetes KW - metabolic syndrome KW - energy harvest KW - diet KW - absorption KW - bile acids KW - low-grade inflammation KW - SCFA Y1 - 2018 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:kobv:517-opus4-407687 ER - TY - JOUR A1 - Krstic, Jelena A1 - Reinisch, Isabel A1 - Schupp, Michael A1 - Schulz, Tim Julius A1 - Prokesch, Andreas T1 - p53 functions in adipose tissue metabolism and homeostasis JF - International journal of molecular sciences N2 - As a tumor suppressor and the most frequently mutated gene in cancer, p53 is among the best-described molecules in medical research. As cancer is in most cases an age-related disease, it seems paradoxical that p53 is so strongly conserved from early multicellular organisms to humans. A function not directly related to tumor suppression, such as the regulation of metabolism in nontransformed cells, could explain this selective pressure. While this role of p53 in cellular metabolism is gradually emerging, it is imperative to dissect the tissue-and cell-specific actions of p53 and its downstream signaling pathways. In this review, we focus on studies reporting p53's impact on adipocyte development, function, and maintenance, as well as the causes and consequences of altered p53 levels in white and brown adipose tissue (AT) with respect to systemic energy homeostasis. While whole body p53 knockout mice gain less weight and fat mass under a high-fat diet owing to increased energy expenditure, modifying p53 expression specifically in adipocytes yields more refined insights: (1) p53 is a negative regulator of in vitro adipogenesis; (2) p53 levels in white AT are increased in diet-induced and genetic obesity mouse models and in obese humans; (3) functionally, elevated p53 in white AT increases senescence and chronic inflammation, aggravating systemic insulin resistance; (4) p53 is not required for normal development of brown AT; and (5) when p53 is activated in brown AT in mice fed a high-fat diet, it increases brown AT temperature and brown AT marker gene expression, thereby contributing to reduced fat mass accumulation. In addition, p53 is increasingly being recognized as crucial player in nutrient sensing pathways. Hence, despite existence of contradictory findings and a varying density of evidence, several functions of p53 in adipocytes and ATs have been emerging, positioning p53 as an essential regulatory hub in ATs. Future studies need to make use of more sophisticated in vivo model systems and should identify an AT-specific set of p53 target genes and downstream pathways upon different (nutrient) challenges to identify novel therapeutic targets to curb metabolic diseases KW - p53 KW - adipose tissue KW - metabolic syndrome KW - obesity KW - adipogenesis KW - insulin resistance Y1 - 2018 U6 - https://doi.org/10.3390/ijms19092622 SN - 1422-0067 VL - 19 IS - 9 PB - MDPI CY - Basel ER - TY - JOUR A1 - Karuwanarint, Piyaporn A1 - Phonrat, Benjaluck A1 - Tungtrongchitr, Anchalee A1 - Suriyaprom, Kanjana A1 - Chuengsamarn, Somlak A1 - Schweigert, Florian J. A1 - Tungtrongchitr, Rungsunn T1 - Vitamin D-binding protein and its polymorphisms as a predictor for metabolic syndrome JF - Biomarkers in medicine N2 - Aim: To investigate the relationship of vitamin D-binding protein (GC) and genetic variation of GC (rs4588, rs7041 and rs2282679) with metabolic syndrome (MetS) in the Thai population. Materials & methods: GCglobulin concentrations were measured by quantitative western blot analysis in 401 adults. All participants were genotyped using TaqMan allelic discrimination assays. Results: GC-globulin levels were significatly lower in MetS subjects than in control subjects, in which significant negative correlations of GC-globulin levels with systolic blood pressure, glucose and age were found. Male participants who carried the GT genotype for rs4588 showed an increased risk of MetS compared with the GG wild-type (odds ratio: 3.25; p = 0.004). Conclusion: GC-globulin concentrations and variation in GC rs4588 were supported as a risk factor for MetS in Thais. KW - GC gene KW - GC-globulin KW - metabolic syndrome KW - polymorphism KW - Thai population KW - vitamin D-binding protein Y1 - 2018 U6 - https://doi.org/10.2217/bmm-2018-0029 SN - 1752-0363 SN - 1752-0371 VL - 12 IS - 5 SP - 465 EP - 473 PB - Future Medicine CY - London ER - TY - GEN A1 - Krstic, Jelena A1 - Reinisch, Isabel A1 - Schupp, Michael A1 - Schulz, Tim Julius A1 - Prokesch, Andreas T1 - p53 functions in adipose tissue metabolism and homeostasis T2 - Postprints der Universität Potsdam : Mathematisch-Naturwissenschaftliche Reihe N2 - As a tumor suppressor and the most frequently mutated gene in cancer, p53 is among the best-described molecules in medical research. As cancer is in most cases an age-related disease, it seems paradoxical that p53 is so strongly conserved from early multicellular organisms to humans. A function not directly related to tumor suppression, such as the regulation of metabolism in nontransformed cells, could explain this selective pressure. While this role of p53 in cellular metabolism is gradually emerging, it is imperative to dissect the tissue-and cell-specific actions of p53 and its downstream signaling pathways. In this review, we focus on studies reporting p53's impact on adipocyte development, function, and maintenance, as well as the causes and consequences of altered p53 levels in white and brown adipose tissue (AT) with respect to systemic energy homeostasis. While whole body p53 knockout mice gain less weight and fat mass under a high-fat diet owing to increased energy expenditure, modifying p53 expression specifically in adipocytes yields more refined insights: (1) p53 is a negative regulator of in vitro adipogenesis; (2) p53 levels in white AT are increased in diet-induced and genetic obesity mouse models and in obese humans; (3) functionally, elevated p53 in white AT increases senescence and chronic inflammation, aggravating systemic insulin resistance; (4) p53 is not required for normal development of brown AT; and (5) when p53 is activated in brown AT in mice fed a high-fat diet, it increases brown AT temperature and brown AT marker gene expression, thereby contributing to reduced fat mass accumulation. In addition, p53 is increasingly being recognized as crucial player in nutrient sensing pathways. Hence, despite existence of contradictory findings and a varying density of evidence, several functions of p53 in adipocytes and ATs have been emerging, positioning p53 as an essential regulatory hub in ATs. Future studies need to make use of more sophisticated in vivo model systems and should identify an AT-specific set of p53 target genes and downstream pathways upon different (nutrient) challenges to identify novel therapeutic targets to curb metabolic diseases. T3 - Zweitveröffentlichungen der Universität Potsdam : Mathematisch-Naturwissenschaftliche Reihe - 1047 KW - p53 KW - adipose tissue KW - metabolic syndrome KW - obesity KW - adipogenesis KW - insulin resistance Y1 - 2020 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:kobv:517-opus4-469069 SN - 1866-8372 IS - 1047 ER - TY - JOUR A1 - Osei, Francis A1 - Block, Andrea A1 - Wippert, Pia-Maria T1 - Association of primary allostatic load mediators and metabolic syndrome (MetS): A systematic review JF - Frontiers in Endocrinology N2 - Allostatic load (AL) exposure may cause detrimental effects on the neuroendocrine system, leading to metabolic syndrome (MetS). The primary mediators of AL involve serum dehydroepiandrosterone sulfate (DHEAS; a functional HPA axis antagonist); further, cortisol, urinary norepinephrine (NE), and epinephrine (EPI) excretion levels (assessed within 12-h urine as a golden standard for the evaluation of the HPA axis activity and sympathetic nervous system activity). However, the evidence of an association between the primary mediators of AL and MetS is limited. This systematic review aimed to critically examine the association between the primary mediators of AL and MetS. PubMed and Web of Science were searched for articles from January 2010 to December 2021, published in English. The search strategy focused on cross-sectional and case–control studies comprising adult participants with MetS, obesity, overweight, and without chronic diseases. The STROBE checklist was used to assess study quality control. Of 770 studies, twenty-one studies with a total sample size (n = 10,666) met the eligibility criteria. Eighteen studies were cross-sectional, and three were case–control studies. The included studies had a completeness of reporting score of COR % = 87.0 ± 6.4%. It is to be noted, that cortisol as a primary mediator of AL showed an association with MetS in 50% (urinary cortisol), 40% (serum cortisol), 60% (salivary cortisol), and 100% (hair cortisol) of the studies. For DHEAS, it is to conclude that 60% of the studies showed an association with MetS. In contrast, urinary EPI and urinary NE had 100% no association with MetS. In summary, there is a tendency for the association between higher serum cortisol, salivary cortisol, urinary cortisol, hair cortisol, and lower levels of DHEAS with MetS. Future studies focusing on longitudinal data are warranted for clarification and understanding of the association between the primary mediators of AL and MetS. KW - allostatic load KW - cortisol KW - dehydroepiandrosterone sulfate KW - epinephrine KW - norepinephrine KW - metabolic syndrome KW - primary marker Y1 - 2022 U6 - https://doi.org/10.3389/fendo.2022.946740 SN - 1664-2392 VL - 13 PB - Frontiers CY - Lausanne, Schweiz ER - TY - GEN A1 - Osei, Francis A1 - Block, Andrea A1 - Wippert, Pia-Maria T1 - Association of primary allostatic load mediators and metabolic syndrome (MetS): A systematic review T2 - Zweitveröffentlichungen der Universität Potsdam : Gesundheitswissenschaftliche Reihe N2 - Allostatic load (AL) exposure may cause detrimental effects on the neuroendocrine system, leading to metabolic syndrome (MetS). The primary mediators of AL involve serum dehydroepiandrosterone sulfate (DHEAS; a functional HPA axis antagonist); further, cortisol, urinary norepinephrine (NE), and epinephrine (EPI) excretion levels (assessed within 12-h urine as a golden standard for the evaluation of the HPA axis activity and sympathetic nervous system activity). However, the evidence of an association between the primary mediators of AL and MetS is limited. This systematic review aimed to critically examine the association between the primary mediators of AL and MetS. PubMed and Web of Science were searched for articles from January 2010 to December 2021, published in English. The search strategy focused on cross-sectional and case–control studies comprising adult participants with MetS, obesity, overweight, and without chronic diseases. The STROBE checklist was used to assess study quality control. Of 770 studies, twenty-one studies with a total sample size (n = 10,666) met the eligibility criteria. Eighteen studies were cross-sectional, and three were case–control studies. The included studies had a completeness of reporting score of COR % = 87.0 ± 6.4%. It is to be noted, that cortisol as a primary mediator of AL showed an association with MetS in 50% (urinary cortisol), 40% (serum cortisol), 60% (salivary cortisol), and 100% (hair cortisol) of the studies. For DHEAS, it is to conclude that 60% of the studies showed an association with MetS. In contrast, urinary EPI and urinary NE had 100% no association with MetS. In summary, there is a tendency for the association between higher serum cortisol, salivary cortisol, urinary cortisol, hair cortisol, and lower levels of DHEAS with MetS. Future studies focusing on longitudinal data are warranted for clarification and understanding of the association between the primary mediators of AL and MetS. T3 - Zweitveröffentlichungen der Universität Potsdam : Gesundheitswissenschaftliche Reihe - 6 KW - allostatic load KW - cortisol KW - dehydroepiandrosterone sulfate KW - epinephrine KW - norepinephrine KW - metabolic syndrome KW - primary marker Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:kobv:517-opus4-581769 IS - 6 ER -